Nautilus and Hilal Lashuel’s lab at Weill Cornell Medicine‑Qatar launched a collaboration backed by $1.6 million from the Michael J. Fox Foundation to apply Nautilus’s single‑molecule proteomics and iterative mapping to alpha‑synuclein (aSyn) proteoforms in Parkinson’s disease. The project aims to measure a broad panel of post‑translationally modified aSyn species at single‑molecule resolution to inform diagnostics and target selection. Lashuel’s group will supply proteoform standards and PTM‑specific antibodies; Nautilus will deploy its Iterative Mapping of Proteoforms platform and antibody‑probing workflow. The partners expect to build assays for diverse aSyn forms in models and human tissues, potentially improving biomarker granularity for stratifying patients and tracking disease progression. Funded by MJFF and tied to Nautilus’s early access program, the collaboration underscores demand for single‑molecule proteomics in neurodegeneration and could yield new tools for clinical development and target validation.